Public Health Leaders, Researchers, and Activists Launch Global Campaign to Revolutionize Tuberculosis Prevention and Treatmnt with New, Shorter, Stronger, Safer, Evidence-Based Regimens
Statement / Press • 2022As public health leaders, researchers, and civil society activists acting in solidarity with communities affected by tuberculosis (TB), we are dismayed by the continued global backslide in progress against history’s oldest pandemic.
Storytelling to Support TB Preventive Treatment (TPT)
Publication • 2022Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. The storyboards on this page describe the experiences of people who took TB preventive treatment (TPT). Daud Yamikani of Malawi took a three-month regimen called…
Treatment Action Group Statement: U.S. District Court Ruling Allowing Employers to Deny PrEP Coverage Is a Dangerous Attack on Public Health
Statement / Press • 2022Treatment Action Group (TAG) unequivocally condemns the September 2022 U.S. District Court ruling in Fort Worth, Texas on the case Braidwood Management Inc. et al., v. Xavier Becerra et al., which ruled that the Affordable Care Act’s requirement that employers cover pre-exposure prophylaxis (PrEP) for HIV prevention was unconstitutional.
The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation
Statement / Press • 2022As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.
New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment
Statement / Press • 2022We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Statement / Press • 2022Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.
Let’s Talk! HIV Vaccines 101
Webinars • 2022On May 18, 2022, Treatment Action Group (TAG), the Black AIDS Institute (BAI), and the Southern AIDS Coalition (SAC) participated in this fun and informative Instagram Live discussion commemorating HIV Vaccine Awareness. Day.
From Evidence to Action: Community-led Monitoring for Access to TB Screening and Diagnostic Testing
Webinars • 2022Treatment Action Group (TAG) and the Coalition of Women Living with HIV and AIDS (COWLHA) hosted this webinar on how community-led monitoring (CLM) can be used to assess, document, and improve the availability, accessibility, acceptability, and quality of local TB screening and diagnostic services.